Labcorp二季度业绩超预期并上调全年收入和调整后EPS指引

AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
Introduction & Market Context
Labcorp Holdings (NYSE:LH) released its second quarter 2026 supplemental financial information on July 30, 2026, showcasing results that exceeded Wall Street expectations and prompted the company to raise its full-year outlook. The diagnostics and biopharma services provider reported adjusted earnings of $4.99 per share, beating the consensus estimate of $4.79, while revenue of $3.73 billion rose 5.8% year-over-year and edged past forecasts.
The company’s stock traded at $310.64, up 1.14% from the previous close of $307.15, positioning shares near their 52-week high of $315.77. The results marked the fifth consecutive quarter of operating margin expansion for Labcorp, suggesting sustained operational efficiency gains alongside revenue growth.
Quarterly Performance Highlights
Labcorp’s enterprise revenue reached $3.73 billion in the second quarter, driven by 4.2% organic growth, 1.2% from acquisitions, and a 0.4% benefit from foreign exchange translation. The company’s adjusted operating margin expanded 70 basis points to 15.8%, up from 15.1% in the prior-year period, reflecting improved operational leverage across both business segments.
As shown in the following breakdown of revenue by segment and geography, the company’s Diagnostics Laboratories business continues to dominate the revenue mix while international operations represent a meaningful portion of total sales.
The Diagnostics Laboratories segment generated $2.90 billion in revenue, up 5.5% year-over-year, with essentially no impact from foreign exchange. Meanwhile, Biopharma Laboratory Services posted $836 million in revenue, representing 6.5% growth that included a 1.8% benefit from currency translation. On a constant currency basis, Biopharma grew 4.7%.
The company’s adjusted EBITDA reached $686.2 million in the quarter, demonstrating the operational leverage inherent in the business model. The following quarterly financial metrics illustrate the trend in profitability and leverage ratios over the past year.
Segment Performance Analysis
Within the Diagnostics segment, Labcorp continued to shift its revenue mix toward higher-value esoteric testing, which reached 41.0% of the segment’s revenue in the second quarter, up from 40.4% in the first quarter and 38.2% in early 2024. This shift reflects the company’s strategic focus on specialty testing areas including oncology, neurology, autoimmune disease, and women’s health, which management noted have been growing at double-digit rates.
The payer mix in Diagnostics showed patient-pay revenue increasing to 14.0% of segment revenue, up from 12.8% in the first quarter, while client revenue declined to 28.9% from 29.5%. Third-party payers represented 46.8% of revenue, down slightly from 47.3% in the prior quarter.
The Biopharma Laboratory Services segment demonstrated accelerating momentum, with the quarterly book-to-bill ratio reaching 1.14 in the second quarter, indicating net orders of $953.2 million exceeded revenue. This represented a significant increase from net orders of $736.2 million in the first quarter of 2026.
The following table details the trailing twelve-month performance and backlog position for the Biopharma segment, which provides visibility into future revenue conversion.
The segment’s backlog stood at $8.73 billion as of June 30, 2026, with an estimated $2.75 billion expected to convert to revenue over the next twelve months. Central Laboratories, the larger business unit within Biopharma, generated $609.3 million in quarterly revenue, while Early Development Research Labs contributed $226.9 million.
Foreign Exchange Impact & Growth Drivers
Foreign exchange translation provided a modest tailwind to reported results in the quarter, contributing $15 million to enterprise revenue growth, or approximately 0.4%. The impact was more pronounced in the Biopharma segment, where currency translation added $14 million, or 1.8% to reported growth.
The following tables illustrate the foreign exchange impact on both quarterly and year-to-date revenue performance across segments.
On a year-to-date basis through June 30, 2026, foreign exchange contributed $59 million to enterprise revenue, representing 0.9% of the 5.8% reported growth rate. The Biopharma segment benefited more substantially, with $54 million or 3.6% of its year-to-date growth attributable to currency movements.
Financial Position & Cash Flow
Labcorp’s balance sheet metrics remained within management’s target ranges, with total debt to last twelve months adjusted EBITDA at 2.4x and net debt to adjusted EBITDA at 2.3x as of June 30, 2026. These leverage ratios have remained relatively stable over the past year, ranging between 2.1x and 2.6x for total debt and 2.1x and 2.3x for net debt.
Free cash flow declined to $314 million in the second quarter from $543 million in the prior-year period, primarily due to working capital timing and higher capital expenditures. The company maintained its full-year free cash flow guidance of $1.24 billion to $1.36 billion, suggesting an expectation for stronger cash generation in the second half of the year.
Depreciation expense was $97.5 million in the quarter, while amortization of intangibles and other assets totaled $78.1 million, reflecting the company’s acquisition-driven growth strategy and ongoing technology investments.
Pricing, Volume & Operating Metrics
The Diagnostics Laboratories segment’s revenue growth in the second quarter was driven by a balanced combination of volume and pricing gains. Volume, measured in requisitions, increased 3.0% year-over-year, while price and mix contributed an additional 2.5% to revenue growth.
This represented a slight moderation from earlier quarters, with price/mix contribution declining from 3.7% in the third quarter of 2025 and 4.0% in the second quarter of 2025. The trend suggests pricing power remains positive but is normalizing from elevated levels seen in prior periods.
Updated 2026 Guidance
Based on the strong first-half performance, Labcorp raised its full-year 2026 guidance across multiple metrics. The updated outlook reflects increased confidence in organic growth drivers, particularly in specialty testing and biopharma services.
The following comparison shows the previous and updated guidance ranges for key financial metrics.
The company now expects adjusted earnings per share of $18.10 to $18.55, representing a $0.30 increase at the midpoint from the prior range of $17.70 to $18.35. Enterprise revenue growth guidance was raised to 5.4% to 6.3%, up from the previous 5.0% to 6.1% range.
The most significant revision came in the Biopharma Laboratory Services segment, where the revenue growth outlook was increased to 5.5% to 6.5% from the prior 3.8% to 5.4% range. This substantial upgrade reflects improving market conditions, stronger study starts, and the segment’s healthy backlog position.
Diagnostics Laboratories revenue growth guidance was modestly increased to 5.3% to 6.0% from 5.1% to 5.9%. The updated enterprise guidance includes an expected 0.4% benefit from foreign currency translation, while the Biopharma guidance incorporates a 1.5% currency tailwind.
GAAP to Non-GAAP Reconciliation
Labcorp’s adjusted financial metrics exclude significant items that the company views as non-recurring or not reflective of underlying operational performance. For the second quarter of 2026, the reconciliation from GAAP to non-GAAP results shows substantial adjustments.
The following summary reconciliation illustrates the bridge from GAAP to adjusted operating income and net income for both the quarterly and year-to-date periods.
Operating income on a GAAP basis was $451.6 million in the second quarter, compared to adjusted operating income of $588.7 million. The $137.1 million difference primarily consisted of $78.1 million in amortization of intangibles, $21.3 million in acquisition and disposition-related costs, $11.7 million in LaunchPad business transformation costs, and $20.9 million in other adjustments.
On a net income basis, GAAP earnings were $298.7 million, or $3.64 per diluted share, compared to adjusted net income of $409.2 million, or $4.99 per share. The tax impact of these adjustments reduced the provision for income taxes by $34.9 million in the quarter.
For the six months ended June 30, 2026, GAAP operating income was $832.4 million compared to adjusted operating income of $1.10 billion, while GAAP net income of $576.5 million compared to adjusted net income of $761.6 million.
Strategic Positioning & Market Outlook
Labcorp’s presentation emphasized the company’s positioning to outpace the broader diagnostic testing market, which management described as growing at 1% to 2% annually. The company’s focus on specialty testing, consumer-initiated testing through Labcorp OnDemand, and expansion of early development services in biopharma positions it to capture higher-growth market segments.
The shift toward esoteric testing is particularly significant, as these higher-complexity tests typically command better pricing and margins than routine testing. With the esoteric mix now exceeding 41% of Diagnostics revenue and continuing to grow, this trend supports both revenue growth and margin expansion.
In the Biopharma segment, the stabilization of study starts and the strong book-to-bill ratio of 1.14 suggest improving market conditions after a period of uncertainty in the clinical trial services market. The $8.73 billion backlog provides substantial revenue visibility, with approximately $2.75 billion expected to convert over the next twelve months.
Management’s commentary on the earnings call highlighted continued investment in technology and artificial intelligence tools, a robust M&A pipeline with strict financial hurdles, and expectations for continued margin expansion in both segments through the remainder of 2026.
The company’s capital allocation strategy balances growth investments, debt management, and shareholder returns, with any acquisition required to be accretive in the first year and earn back capital within two to three years. Capital expenditures are expected to remain at approximately 4% of revenue for the full year.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.